ICIs (e.g., PD-1/PD-L1 inhibitors) may, by blocking the immune checkpoint signaling of B cells, restore the proliferation, activation, antigen presentation, and co-stimulatory functions, thereby assisting T cells in exerting anti-tumor effects. Here, PDCD1 is linked to neoplasm.